Trump FDA nominee played key role in overhaul of childhood vaccine policy

Heidi Overton, Donald Trump’s nominee to lead the Food and Drug Administration, played a pivotal role in reducing the number of vaccines recommended for children, contrary to the lesser-known aspects of her Senate confirmation process. As an aide on the president’s Domestic Policy Council, Overton contributed to drafting a scientific justification for the reduction in CDC vaccine recommendations from 17 to 11.

This effort, according to senior administration officials and individuals familiar with the process, was spearheaded by Overton, who is also a former senior administration official. Health Secretary Robert F. Kennedy Jr. endorsed the policy push, which aimed to streamline the childhood immunization schedule. Overton’s contributions were instrumental in aligning various health agencies around the new schedule, meeting with Trump administration officials including Kennedy, former FDA Commissioner Marty Makary, and others.

Despite her role in shaping the policy, Overton’s commitment to vaccine safety was questioned during her Senate confirmation hearing in September. When asked if she would stand up to Trump if he asked her to act against the American people’s trust, Overton stated that she would provide him with her best advice. The nomination of Overton, who has faced criticism from some activists, was met with concerns that she would be too aligned with pharmaceutical interests.

However, her responsibilities at the White House involved translating the president’s directives into a document suitable for distribution, reflecting a top-down policy approach rather than her personal views.